About
Type 2 Diabetes
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule PharmaceuticalBiotech
Clinical Trials (26)
View allTotal Trials
26
As Lead Sponsor
25
As Collaborator
1
Total Enrollment
2,371
By Phase
PHASE2: 10PHASE2/PHASE3: 1PHASE1: 11PHASE1/PHASE2: 4
By Status
COMPLETED: 20ACTIVE_NOT_RECRUITING: 3RECRUITING: 1WITHDRAWN: 1TERMINATED: 1
Clinical Trials Pipeline26 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT07033026Lead Sponsor
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
PHASE2Recruiting
136 participants
Started: Jun 30, 2025 · Completed: Dec 31, 2027
NCT06654726Lead Sponsor
A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.
PHASE2/PHASE3Withdrawn
Started: Oct 21, 2024 · Completed: Mar 18, 2025
NCT05311618Lead Sponsor
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
PHASE1Active, not recruiting
71 participants
Started: May 11, 2022 · Completed: Jun 30, 2025
NCT05215574Lead Sponsor
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
PHASE1Active, not recruiting
130 participants
Started: Mar 31, 2022 · Completed: Mar 31, 2026
NCT05130047Collaborator
Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
PHASE2Completed
30 participants
Started: Dec 1, 2021 · Completed: Nov 8, 2022
Locations (1)
Headquarters
South SF, CA, United States
Map
Loading map...